Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients
Chronic Kidney Diseases, Hemodialysis Complication, Hyperphosphatemia
About this trial
This is an interventional treatment trial for Chronic Kidney Diseases focused on measuring chronic kidney disease, hyperphosphatemia in chronic adult hemodialysis patients, bile acid sequestrants: cholestyramine, serum calcium level, serum phosphate level
Eligibility Criteria
Inclusion Criteria:
• Patients aged ≥18 years with CKD stage (4&5)
- Serum phosphate level ≥ 5.5 mg/dL
- Serum LDL-C level ≥1.82 mmol/L (70 mg/dL)
- Hemodialysis frequency 3 times per week or more.
- Hemodialysis in the last 3 months or longer.
Exclusion Criteria:
Patients are excluded if they have a history of clinically significant gastrointestinal motility disorder, dysphagia, or swallowing disorder.
2-patients require warfarin or digoxin treatment. 3- Patients have a history of alcohol or substance abuse 4- Patients receiving calcimimetics. 5- Pregnant patients or patients planning pregnancy. 6- Patients have Triglyceride level above 300 (mg/dl)
Sites / Locations
- Ain Shams university
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Test group
Control group
Group 1: (cholestyramine 12 gram), 40 patients will take a dose of cholestyramine 4-gram sachet in 150-200 ml water or juice three times daily within meals as an add-on therapy with standard therapy calcium-based phosphate binder (Calcimate). Dosage: one sachet on 150 ml water three times daily duration : 8 weeks
Group 2: Control group, 40 patients will take only the standard therapy calcium-based phosphate binder (Calcimate).